Navigation Links
Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
Date:10/3/2008

New Rochelle, NY, October 3, 2008Novel platform technologies and key advances in genomics are rapidly driving the development of molecular diagnostics, reports Genetic Engineering and Biotechnology News (GEN). The payoff for successful molecular diagnostic products can be significant as Kalorama Information predicts that this market currently exceeds $3.2 billion worldwide and will reach $5.4 billion in four years, according to an article in the October 1 issue of GEN.

"Molecular diagnostic products are based on cutting-edge research in two of the most promising biotechnologies, genomics and proteomics. These novel tests also utilize sophisticated analytical techniques such as microarrays and mass spectrometry," notes John Sterling, Editor-in-Chief of GEN. "Molecular diagnostics are particularly applicable to the early detection of cancer."

Affymetrix and Illumina have both created array-based products that enable high-speed analysis of DNA, RNA, and proteins as tools for disease research, drug development, and molecular tests. These gene-sequencing tools are being applied at an earlier stage.

Genetic tests can optimize drug therapy, and companion diagnostics are being touted as a method to better define a patient's need or predict clinical outcome from a specific drug. The FDA recently approved a HER-2 test from Invitrogen called Spot-Light that can be used to identify breast cancer patients who are candidates for treatment with Herceptin. In addition, data was recently presented showing the importance of testing for the K-ras gene to assess the clinical benefit of Erbitux for metastatic colorectal cancer.

Of all the larger integrated healthcare companies, Roche has best executed the synergies of molecular diagnostics and biopharmaceuticals and is well positioned for the future with products in oncology and infectious disease. Its genetic tests include CYP450 for drug metabolism studies and HER-2 for use with tamoxifen therapy.

Other companies covered in the GEN article include Myriad Genetics, Genomic Health, Genoptix, Luminex, Abbott Labs, Aureon, Autogenomics, Nanosphere, Navigenics, Osmetech, and Perlegen Sciences.


'/>"/>

Contact: John Sterling
jsterling@genengnews.com
914-740-2196
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Related biology news :

1. Does the desire to consume alcohol and tobacco come from our genetic makeup?
2. Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
3. Many parents at-risk for cancer disclose genetic test results to children
4. Genetics determine optimal drug dose of common anticoagulant
5. Claims of sex-related differences in genetic association studies often not properly validated
6. American College of Medical Genetics responds to new FDA labeling decision for warfarin
7. UNC study questions FDA genetic-screening guidelines for cancer drug
8. Genome study shines light on genetic link to height
9. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
10. Genes, Environment and Health Initiative invests in genetic studies, environmental monitoring
11. Rutgers Genetics receives $7.8 million for autism research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... , March 21, 2017 Vigilant Solutions ... serving law enforcement agencies, announced today the appointment of ... director of public safety business development. Mr. ... enforcement experience, including a focus on the aviation transportation ... most recent position, Mr. Sheridan served as the Aviation ...
(Date:3/13/2017)... March 13, 2017 Future of security: Biometric Face Matching ... ... DERMALOGs Face Matching enables to match face pictures against each ... to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching on ...
(Date:3/7/2017)... , March 7, 2017   HireVue , the ... global companies identify the best talent, faster, today announced ... Sales Officer (CSO) and Diana Kucer as ... out a seasoned executive team poised to drive continued growth ... on a year of record bookings in 2017. ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... ... March 28, 2017 , ... T3D Therapeutics, Inc., a ... administered treatment for Alzheimer’s disease (AD), today announced that Dr. Kathleen Welsh-Bohmer has ... to uniquely treat the metabolic dysfunctions inherent in Alzheimer’s disease and advance the ...
(Date:3/27/2017)... , March 27, 2017 Roka Bioscience, Inc. (NASDAQ: ... solutions for the detection of foodborne pathogens,  today announced that ... & Company Spring 2017 Convention on March 29 at 9:50am ... Marriott Marquis. About Roka Bioscience ... Roka Bioscience ...
(Date:3/27/2017)... March 27, 2017 Cousins Properties (NYSE: ... leading biotechnology companies, has signed a 10-year, approximately 125,000 square-foot ... office asset located in the Westshore submarket of ... that Amgen has chosen Corporate Center for their new location ... , president and chief executive officer of Cousins Properties. "Amgen ...
(Date:3/27/2017)... a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today announced positive results ... regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is a new small molecule ... US National Institutes of Health. Continue Reading ... ... ...
Breaking Biology Technology: